AstraZeneca’s Lupus drug fails to meet trial target

Share this article!

Astrazeneca's (LON:AZN) Lupus treatment, Anifrolumab has not met the target of its late stage TULIP 1 Phase III trial. The study found that Lupus patients who used the treatment did not see a significant reduction in the activity of the disease, compared with other patients who had received a placebo.

The Lupus treatment, Anifroumab (an antibody that suppresses cell reception to reduce inflammation) is just one of three treatments currently being tested by pharmaceutical companies, with AstraZeneca competing against GlaxoSmithKline (LON:GSK) and Neovacs – both of which are in test stages with their own Lupus treatments.

Early results were hopeful

AstraZeneca’s Anifrolumab initially showed promising results in early tests with Astrazeneca staff hopeful that this would be one of the first successful Lupus treatments to enter the market in 60 years. However, end stage tests results did not meet the company’s end goal, nor did test patients show any significant improvement after long-term use.

AstraZeneca’s executive Vice President IG Global medicine development Sean Bohen commented on the pharmaceutical companies over the later stage test results: "The result of this trial is disappointing for patients and the lupus community.” as reported in Reuters. 

As of 14:35 BST, Friday, 31 August, AstraZeneca plc share price is 4,922.25p.

Add Comment

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.